Last reviewed 2026-04-19 · How we verify

Melan-A VLP vaccine, IMP321 adjuvant

Prof. Serge Leyvraz · Phase 1 active Biologic

Melan-A VLP vaccine, IMP321 adjuvant is a Biologic drug developed by Prof. Serge Leyvraz. It is currently in Phase 1 development.

At a glance

Generic name	Melan-A VLP vaccine, IMP321 adjuvant
Sponsor	Prof. Serge Leyvraz
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Melan-A VLP vaccine, IMP321 adjuvant CI brief — competitive landscape report
Melan-A VLP vaccine, IMP321 adjuvant updates RSS · CI watch RSS
Prof. Serge Leyvraz portfolio CI

Frequently asked questions about Melan-A VLP vaccine, IMP321 adjuvant

What is Melan-A VLP vaccine, IMP321 adjuvant?

Melan-A VLP vaccine, IMP321 adjuvant is a Biologic drug developed by Prof. Serge Leyvraz.

Who makes Melan-A VLP vaccine, IMP321 adjuvant?

Melan-A VLP vaccine, IMP321 adjuvant is developed by Prof. Serge Leyvraz (see full Prof. Serge Leyvraz pipeline at /company/prof-serge-leyvraz).

What development phase is Melan-A VLP vaccine, IMP321 adjuvant in?

Melan-A VLP vaccine, IMP321 adjuvant is in Phase 1.

Manufacturer: Prof. Serge Leyvraz — full pipeline